Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome
- PMID: 27965259
- PMCID: PMC5530351
- DOI: 10.1136/annrheumdis-2016-210448
Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome
Abstract
Labial salivary gland (LSG) biopsy is used in the classification of primary Sjögren's syndrome (PSS) and in patient stratification in clinical trials. It may also function as a biomarker. The acquisition of tissue and histological interpretation is variable and needs to be standardised for use in clinical trials. A modified European League Against Rheumatism consensus guideline development strategy was used. The steering committee of the ad hoc working group identified key outstanding points of variability in LSG acquisition and analysis. A 2-day workshop was held to develop consensus where possible and identify points where further discussion/data was needed. These points were reviewed by a subgroup of experts on PSS histopathology and then circulated via an online survey to 50 stakeholder experts consisting of rheumatologists, histopathologists and oral medicine specialists, to assess level of agreement (0-10 scale) and comments. Criteria for agreement were a mean score ≥6/10 and 75% of respondents scoring ≥6/10. Thirty-nine (78%) experts responded and 16 points met criteria for agreement. These points are focused on tissue requirements, identification of the characteristic focal lymphocytic sialadenitis, calculation of the focus score, identification of germinal centres, assessment of the area of leucocyte infiltration, reporting standards and use of prestudy samples for clinical trials. We provide standardised consensus guidance for the use of labial salivary gland histopathology in the classification of PSS and in clinical trials and identify areas where further research is required to achieve evidence-based consensus.
Keywords: Autoimmunity; Outcomes research; Sjøgren's Syndrome.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: SJB has received honoraria/consultancy fees in the field of Sjögren's syndrome in 2015–2016 for AstraZeneca, Celgene, Glenmark, Eli Lilly, Novartis, Ono and UCB Pharmaceuticals. Roche provided rituximab for the TRACTISS study. BAF has received honoraria/consultancy fees from Novartis, Roche and Medimmune. FB has received honoraria/consultancy fees from Roche, GlaxoSmithKline, Glenmark and Medimmune, and research funding from UCB. Other authors have declared no competing interests.
Figures



Comment in
-
Standardisation of labial salivary gland biopsies in Sjogren's syndrome: importance for the practicing rheumatologist.Ann Rheum Dis. 2017 Jul;76(7):1159-1160. doi: 10.1136/annrheumdis-2016-210851. Epub 2017 Mar 2. Ann Rheum Dis. 2017. PMID: 28254788 No abstract available.
Similar articles
-
Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome.Ann Rheum Dis. 2011 Aug;70(8):1363-8. doi: 10.1136/ard.2010.144782. Ann Rheum Dis. 2011. PMID: 21715359 Free PMC article.
-
Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren's syndrome.Clin Rheumatol. 2014 Apr;33(4):523-9. doi: 10.1007/s10067-013-2476-z. Epub 2014 Jan 14. Clin Rheumatol. 2014. PMID: 24420723
-
Value of minor salivary gland biopsy in diagnosing Sjögren's syndrome.J Otolaryngol. 2002 Oct;31(5):299-303. doi: 10.2310/7070.2002.34324. J Otolaryngol. 2002. PMID: 12512895
-
Labial salivary gland biopsy in Sjögren's syndrome.Neth J Med. 1992 Apr;40(3-4):148-57. Neth J Med. 1992. PMID: 1603205 Review.
-
Biopsy of the lip and Sjögren's syndrome.Ann Otol Rhinol Laryngol. 1990 Apr;99(4 Pt 1):323-5. doi: 10.1177/000348949009900416. Ann Otol Rhinol Laryngol. 1990. PMID: 2183669 Review.
Cited by
-
Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome.F1000Res. 2019 Aug 29;8:F1000 Faculty Rev-1532. doi: 10.12688/f1000research.19842.1. eCollection 2019. F1000Res. 2019. PMID: 31508200 Free PMC article. Review.
-
Mitochondria-related genes and metabolic profiles of innate and adaptive immune cells in primary Sjögren's syndrome.Front Immunol. 2023 Jul 11;14:1156774. doi: 10.3389/fimmu.2023.1156774. eCollection 2023. Front Immunol. 2023. PMID: 37497211 Free PMC article.
-
[Digital pathology : The time has come!].Pathologe. 2018 May;39(3):228-235. doi: 10.1007/s00292-018-0431-0. Pathologe. 2018. PMID: 29691675 Review. German.
-
Elevated expression of Toll-like receptor 7 and its correlation with clinical features in patients with primary Sjögren's syndrome.Adv Rheumatol. 2024 Mar 4;64(1):17. doi: 10.1186/s42358-024-00360-4. Adv Rheumatol. 2024. PMID: 38439071
-
Focal lymphocytic sialadenitis and ectopic germinal centers in oral reactive lesions and primary Sjögren's syndrome: a comparative study.Rheumatol Int. 2022 Aug;42(8):1411-1421. doi: 10.1007/s00296-021-04949-6. Epub 2021 Jul 20. Rheumatol Int. 2022. PMID: 34283264
References
-
- Bowman SJ, Fox RI. Classification criteria for Sjogren's syndrome: nothing ever stands still!. Ann Rheum Dis 2014;73:1–2. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous